SCHEMBL14960573

SCHEMBL14960573

Cc1cccc(C)c1C(=O)N1CCC[C@H](C(=O)Nc2cccc(Cl)c2)[C@@H]1c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.48
▸ HPGD P15428 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ TSHR P16473 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MGLL Q99685 3/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ RIPK1 Q13546 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13060130 1.00 ALDH1A1 (0.48) ALDH1A1HPGDKDM4EHTTTSHR
SCHEMBL18532596 1.00 ALDH1A1 (0.48) ALDH1A1HPGDKDM4EHTTTSHR
SCHEMBL12176498 0.94 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EHTTTSHR
SCHEMBL14959021 0.90 ALDH1A1 (0.56) ALDH1A1TSHRKMT2ACYP1A2CYP2C9
SCHEMBL14959038 0.89 ALDH1A1 (0.45) ALDH1A1HTTTSHRSMN1; SMN2LMNA
SCHEMBL18609476 0.89 ALDH1A1 (0.45) ALDH1A1HTTTSHRSMN1; SMN2LMNA
SCHEMBL12176395 0.87 CYP2C19 (0.51) ALDH1A1KMT2ALMNAMAPT
SCHEMBL25133167 0.87 TRPM8 (0.46) ALDH1A1KMT2ALMNACYP1A2CYP2C9
SCHEMBL18532606 0.87 ALDH1A1 (0.43) ALDH1A1TSHRLMNACYP1A2CYP2C9
SCHEMBL12176191 0.87 ALDH1A1 (0.43) ALDH1A1TSHRLMNACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4015504-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2022-06-22 — — EP disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 — — US disclosed
US-20170065604-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2017-03-09 — — US disclosed
US-9573897-B2 C5AR antagonists CHEMOCENTRYX, INC. (US) 2017-02-21 — — US disclosed
EP-3078658-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2016-10-12 — — EP disclosed
US-20160229802-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2016-08-11 — — US disclosed
EP-2381778-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2016-06-08 — — EP disclosed
US-9126939-B2 C5AR antagonists CHEMOCENTRYX, INC. 2015-09-08 — — US disclosed
US-20150141425-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2015-05-21 — — US disclosed
US-8906938-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2014-12-09 — — US disclosed
US-20130172347-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2013-07-04 — — US disclosed
US-8445515-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2013-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141425-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 ALDH1A1 2966/4885HPGD 2093/4885KDM4E 4012/4885
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 ALDH1A1 2966/4885HPGD 2093/4885KDM4E 4012/4885
US-20160229802-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 ALDH1A1 2966/4885HPGD 2093/4885KDM4E 4012/4885
US-20130172347-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 ALDH1A1 2966/4885HPGD 2093/4885KDM4E 4012/4885
US-20170065604-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 ALDH1A1 2882/4885HPGD 2033/4885KDM4E 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback